Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Aldeyra Therapeutics Inc. (developing therapies for diseases related to endogenous aldehyde toxicity) netted $27mm through the follow-on offering of 3.97mm common shares (including full exercise of the overallotment) priced at $7.25. The company will use some of the proceeds for ongoing development of candidates including its lead program ADX102, which is being developed in different formulations. An ophthalmic solution is in Phase III for noninfectious anterior uveitis and Phase II for allergic conjunctivitis and dry eye syndrome. Topical ADX102 is in Phase III for Sjögren-Larsson syndrome and oral ADX102 is in earlier-stage studies for Sjögren-Larsson syndrome and SSADH deficiency.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?